Blog
RSS FeedPosted by Michael Wonder on 21 Feb 2018
Charity upset pre-election pledge for separate fund for rare diseases off the table
21 February 2018 - The country's biggest charity helping people dealing with rare disorders is upset the Government has gone ...
Posted by Michael Wonder on 19 Feb 2018
New Zealand cancer survival rate worse than Australia's
19 February 2018 - About 2500 New Zealanders would have beaten cancer in the last five years if they had ...
Posted by Michael Wonder on 11 Feb 2018
Cancer patients waiting a year for Keytruda funding decision from PHARMAC
12 February 2018 - Hundreds of lung cancer patients whose lives could be saved by a new treatment labelled a ...
Posted by Michael Wonder on 07 Feb 2018
No political pressure in HIV drug funding call - PHARMAC
7 February 2018 - PHARMAC is rejecting any suggestion it reacted to political pressure to fund a new anti-HIV drug. ...
Posted by Michael Wonder on 05 Feb 2018
New independent chair wants improved equitable access to breakthrough medicines
1 February 2018 - Former clinical leader, Dr. Lee Mathias, has been appointed as new chair for Medicines New Zealand ...
Posted by Michael Wonder on 01 Feb 2018
Advance notice of consultation about changes to the Pharmaceutical Schedule Rules
1 February 2018 - PHARMAC is working to make the Pharmaceutical Schedule Rules easier to find, use and apply. ...
Posted by Michael Wonder on 31 Jan 2018
New Zealand Pharmaceutical Schedule - 1 February 2018
1 February 2018 - The February 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 24 Jan 2018
Proposal to list eplerenone for the treatment of heart failure in patients intolerant to spironolactone
24 January 2018 - Following assessment of bids in PHARMAC’s 2017/18 annual Invitation to Tender, PHARMAC is proposing to fund ...
Posted by Michael Wonder on 15 Jan 2018
PHARMAC approves funding for treatment for 'mighty Mon'
14 January 2018 - A woman fighting cancer for the third time - and who was told she may only ...
Posted by Michael Wonder on 12 Jan 2018
Decision to widen access to pulmonary arterial hypertension treatments
12 January 2018 - PHARMAC is pleased to announce our decision to widen funded access to five treatments for pulmonary ...
Posted by Michael Wonder on 08 Jan 2018
Significant step forward for treating people with head and neck cancer
21 December 2018 - Funding cetuximab for patients with head and neck cancer will be a significant advance for treating ...
Posted by Michael Wonder on 02 Jan 2018
New Zealand Pharmaceutical Schedule - 1 January 2018
1 January 2018 - The January 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 20 Dec 2017
Decision to fund cetuximab for head and neck cancer
20 December 2017 - PHARMAC is pleased to announce our decision to fund cetuximab (Erbitux) from 1 February 2018 for ...
Posted by Michael Wonder on 14 Dec 2017
Up to 3,000 women to benefit from PHARMAC decision
14 December 2017 - Post-menopausal women with early breast cancer will soon be able to have funded zoledronic acid, to ...
Posted by Michael Wonder on 12 Dec 2017
Decision to widen access to various anti-infectives
12 December 2017 - PHARMAC is pleased to announce our decision to widen funded access to three treatments: ...